Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN

https://doi.org/10.20996/1819-6446-2008-4-4-54-58

Full Text:

Abstract

Aim. To study efficacy and tolerability of antihypertensive therapy with enalapril (Berlipril®, Berlin-Chemie AG/Menarini Group) and diltiazem (Altiazem® PP, Berlin-Chemie AG/Menarini Group) in postmenopausal women with arterial hypertension (HT) and climacteric disorders.

Material and methods. 60 postmenopausal women (aged 56,8±3,9 y.o.) with HT of 1-3 degrees were included into the study. They were split in two groups. Patients of the first group (30 people) received enalapril (Berlipril®) 20 mg/daily, patients of the second group (30 people) – diltiazem (Altiazem® PP) 180-360 mg/daily. Observation period was 6 months. Ambulatory blood pressure monitoring (ABPM) was performed before treatment and after 3 weeks, 1, 3 and 6 months of therapy. Climacteric syndrome severity and urodynamic disorders was estimated as well as psychic status according to score of depression and anxiety.

Results. Office and ambulance blood pressure decreased after 6 months of therapy in all patients of both groups. A number of complaints on headache and giddiness reduced significantly. Severity of climacteric syndrome also decreased. Enalapril (Berlipril®) monotherapy and especially combined therapy with hydrochlorothiazide led to aggravation of urodinamic disorders. On the contrary both monotherapy with diltiazem (Altiazem® PP) or its combination with hydrochlorothiazide had positive effect on urodinamics. Both therapies reduced depression and anxiety levels significantly.

Conclusion. All spectrum of pharmacology effects should be taken into account during antihypertensive therapy of patients with climacteric disorders.

About the Authors

A. A. Kirichenko
Russian Medical Academy of Postgraduate Educational, Barrikadnaya ul. 2/1, 123995 Moscow
Russian Federation
Chair of Therapy


Z. M. Tankieva
Russian Medical Academy of Postgraduate Educational, Barrikadnaya ul. 2/1, 123995 Moscow
Russian Federation
Chair of Therapy


References

1. Isles C. Prevention of coronary disease in women. Scott Med J 1993;38:103-6.

2. Migneco A., Ojetti V., Covino M., et al. Increased blood pressure variability in menopause. Eur Rev Med Pharmacol Sci. 2008;12(2):89-95.

3. Sjöberg L., Kaaja R., Tuomilehto J. et al. Epidemiology of postmenopausal hypertension. Int J Clin Pract Suppl. 2004;(139):4-12.

4. Жуковицкий Г.С., Константинов В.В., Варламова Т.А., Капустина А.В. Артериальная гипертензия: эпидемиологическая ситуация в России и других странах. РМЖ 1997;5(9):551-8.

5. van Beresteyn E.C., van t Hof M.A., De Waard H. Contributions of ovarial failure and aging to blood pressure in normotensive perimenopausal women a mixed longitudinal study. Am J Epidemiol 1989;129:947-55.

6. Кириченко А.А. Лечение гипертонической болезни у женщин в постменопаузе. Практикующий врач 2003;(1):31-7.

7. Donmez G., Derici U., Erbas D., et al. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essentiale hypertension. Jpn J Physiol 2002;52(5):435- 40.

8. Jain S., Rajeshwari J., Khullar M., Kumari S. Enalapril acts through release of nitric oxide in patients with essential hypertension. Ren Fail 2001;23(5):651-7.

9. Scribner A.W., Loscalzo J., Napoli C. The effect of angiotensin- converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003;482(l-3):95-9.


For citation:


Kirichenko A.A., Tankieva Z.M. ANTIHYPERTENSIVE THERAPY AND CLIMACTERIC DISORDERS IN POSTMENOPAUSAL WOMEN. Rational Pharmacotherapy in Cardiology. 2008;4(4):54-58. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-54-58

Views: 370


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)